{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:26:40Z","timestamp":1793834800109,"version":"4.6.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273237"],"award-info":[{"award-number":["82273237"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272934"],"award-info":[{"award-number":["82272934"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2021M701778"],"award-info":[{"award-number":["2021M701778"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019539","name":"Science Fund for Distinguished Young Scholars of Tianjin","doi-asserted-by":"publisher","award":["19JCJQJC63200"],"award-info":[{"award-number":["19JCJQJC63200"]}],"id":[{"id":"10.13039\/501100019539","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The immune checkpoint inhibitor (ICI) anti-PD-L1 monoclonal antibody can inhibit the progress of hepatocellular carcinoma (HCC). Epithelial\u2013mesenchymal transformation (EMT) can promote tumor migration and the formation of immune-suppression microenvironment, which affects the therapeutic effect of ICI. Yin-yang-1 (YY1) is an important transcription factor regulating proliferation, migration and EMT of tumor cells. This work proposed a drug-development strategy that combined the regulation of YY1-mediated tumor progression with ICIs for the treatment of HCC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We first studied the proteins that regulated YY1 expression by using pull-down, co-immunoprecipitation, and duo-link assay. The active compound regulating YY1 content was screened by virtual screening and cell-function assay. Isorhamnetin (ISO) and anti-PD-L1 antibody dual-functional mesoporous silica nanoparticles (HMSN-ISO@ProA-PD-L1 Ab) were prepared as an antitumor drug to play a synergistic anti-tumor role.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>YY1 can specifically bind with the deubiquitination enzyme USP7. USP7 can prevent YY1 from ubiquitin-dependent degradation and stabilize YY1 expression, which can promote the proliferation, migration and EMT of HCC cells. Isorhamnetin (ISO) were screened out, which can target USP7 and promote YY1 ubiquitin-dependent degradation. The cell experiments revealed that the HMSN-ISO@ProA-PD-L1 Ab nanoparticles can specifically target tumor cells and play a role in the controlled release of ISO. HMSN-ISO@ProA-PD-L1 Ab nanoparticles inhibited the growth of Hepa1-6 transplanted tumors and the effect was better than that of PD-L1 Ab treatment group and ISO treatment group. HMSN-ISO@ProA-PD-L1 Ab nanoparticles also exerted a promising effect on reducing MDSC content in the tumor microenvironment and promoting T-cell infiltration in tumors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The isorhamnetin and anti-PD-L1 antibody dual-functional nanoparticles can improve tumor immune microenvironment and inhibit YY1-mediated tumor progression. This study demonstrated the possibility of HCC treatment strategies based on inhibiting USP7-mediated YY1 deubiquitination combined with anti-PD-L1 monoclonal Ab.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12951-023-01967-3","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T05:10:10Z","timestamp":1688533810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Isorhamnetin and anti-PD-L1 antibody dual-functional mesoporous silica nanoparticles improve tumor immune microenvironment and inhibit YY1-mediated tumor progression"],"prefix":"10.1186","volume":"21","author":[{"given":"Huijuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxia","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoting","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"1967_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13046-018-0777-4","volume":"37","author":"F Xu","year":"2018","unstructured":"Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018;37:110.","journal-title":"J Exp Clin Cancer Res"},{"key":"1967_CR2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko I, Blanpain C. EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2019;29:212\u201326.","journal-title":"Trends Cell Biol"},{"key":"1967_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.canlet.2019.10.013","volume":"468","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Zhan H. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett. 2020;468:72\u201381.","journal-title":"Cancer Lett"},{"key":"1967_CR4","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1158\/0008-5472.CAN-16-3292","volume":"77","author":"A Dongre","year":"2017","unstructured":"Dongre A, Rashidian M, Reinhardt F, Bagnato A, Keckesova Z, Ploegh HL, Weinberg RA. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 2017;77:3982\u20139.","journal-title":"Cancer Res"},{"key":"1967_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1615\/CritRevOncog.2017020473","volume":"22","author":"AA Cho","year":"2017","unstructured":"Cho AA, Bonavida B. Targeting the overexpressed YY1 in Cancer inhibits EMT and metastasis. Crit Rev Oncog. 2017;22:49\u201361.","journal-title":"Crit Rev Oncog"},{"key":"1967_CR6","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.ajhg.2016.04.012","volume":"98","author":"JN Painter","year":"2016","unstructured":"Painter JN, Kaufmann S, O\u2019Mara TA, Hillman KM, Sivakumaran H, Darabi H, Cheng THT, Pearson J, Kazakoff S, Waddell N, et al. A common variant at the 14q32 Endometrial Cancer Risk Locus activates AKT1 through YY1 binding. Am J Hum Genet. 2016;98:1159\u201369.","journal-title":"Am J Hum Genet"},{"key":"1967_CR7","doi-asserted-by":"publisher","first-page":"24428","DOI":"10.1074\/jbc.M503790200","volume":"280","author":"DY Begon","year":"2005","unstructured":"Begon DY, Delacroix L, Vernimmen D, Jackers P, Winkler R. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J Biol Chem. 2005;280:24428\u201334.","journal-title":"J Biol Chem"},{"key":"1967_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1158\/1541-7786.MCR-08-0229","volume":"7","author":"MB Palmer","year":"2009","unstructured":"Palmer MB, Majumder P, Cooper JC, Yoon H, Wade PA, Boss JM. Yin yang 1 regulates the expression of snail through a distal enhancer. Mol Cancer Res. 2009;7:221\u20139.","journal-title":"Mol Cancer Res"},{"key":"1967_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.drup.2019.04.001","volume":"43","author":"E Hays","year":"2019","unstructured":"Hays E, Bonavida B. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. Drug Resist Updates. 2019;43:10\u201328.","journal-title":"Drug Resist Updates"},{"key":"1967_CR10","doi-asserted-by":"publisher","first-page":"1902634","DOI":"10.1002\/adfm.201902634","volume":"30","author":"M Manzano","year":"2020","unstructured":"Manzano M, Vallet-Reg\u00ed M. Mesoporous silica nanoparticles for drug delivery. Adv Funct Mater. 2020;30:1902634.","journal-title":"Adv Funct Mater"},{"key":"1967_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2020.09.009","volume":"116","author":"R Huang","year":"2020","unstructured":"Huang R, Shen YW, Guan YY, Jiang YX, Wu Y, Rahman K, Zhang LJ, Liu HJ, Luan X. Mesoporous silica nanoparticles: facile surface functionalization and versatile biomedical applications in oncology. Acta Biomater. 2020;116:1\u201315.","journal-title":"Acta Biomater"},{"key":"1967_CR12","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1039\/c1cs15246g","volume":"41","author":"ZX Li","year":"2012","unstructured":"Li ZX, Barnes JC, Bosoy A, Stoddart JF, Zink JI. Mesoporous silica nanoparticles in biomedical applications. Chem Soc Rev. 2012;41:2590\u2013605.","journal-title":"Chem Soc Rev"},{"key":"1967_CR13","doi-asserted-by":"crossref","unstructured":"AbouAitah K, Lojkowski W. Delivery of natural agents by means of mesoporous silica nanospheres as a promising Anticancer Strategy. Pharmaceutics 2021, 13.","DOI":"10.3390\/pharmaceutics13020143"},{"key":"1967_CR14","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1039\/D0NA00219D","volume":"2","author":"P Hao","year":"2020","unstructured":"Hao P, Peng B, Shan BQ, Yang TQ, Zhang K. Comprehensive understanding of the synthesis and formation mechanism of dendritic mesoporous silica nanospheres. Nanoscale Adv. 2020;2:1792\u2013810.","journal-title":"Nanoscale Adv"},{"key":"1967_CR15","doi-asserted-by":"crossref","unstructured":"Flood-Garibay JA, M\u00e9ndez-Rojas MA. Effects of Co-Solvent Nature and Acid Concentration in the size and morphology of wrinkled mesoporous silica nanoparticles for drug delivery applications. Molecules 2021, 26.","DOI":"10.3390\/molecules26144186"},{"key":"1967_CR16","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301\u201314.","journal-title":"Lancet"},{"key":"1967_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1053\/j.semdp.2016.12.011","volume":"34","author":"J Hartke","year":"2017","unstructured":"Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 2017;34:153\u20139.","journal-title":"Semin Diagn Pathol"},{"key":"1967_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cld.2022.08.004","volume":"27","author":"P Ganesan","year":"2023","unstructured":"Ganesan P, Kulik LM. Hepatocellular Carcinoma: New Developments. Clin Liver Dis. 2023;27:85\u2013102.","journal-title":"Clin Liver Dis"},{"key":"1967_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41423-020-00572-w","volume":"18","author":"B Ruf","year":"2021","unstructured":"Ruf B, Heinrich B, Greten TF. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cell Mol Immunol. 2021;18:112\u201327.","journal-title":"Cell Mol Immunol"},{"key":"1967_CR20","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1016\/j.devcel.2021.11.006","volume":"56","author":"F Luond","year":"2021","unstructured":"Luond F, Sugiyama N, Bill R, Bornes L, Hager C, Tang F, Santacroce N, Beisel C, Ivanek R, Burglin T, et al. Distinct contributions of partial and full EMT to breast cancer malignancy. Dev Cell. 2021;56:3203\u20133221e3211.","journal-title":"Dev Cell"},{"key":"1967_CR21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10555-016-9648-7","volume":"35","author":"CL Chaffer","year":"2016","unstructured":"Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016;35:645\u201354.","journal-title":"Cancer Metastasis Rev"},{"key":"1967_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12943-019-0976-4","volume":"18","author":"C Wei","year":"2019","unstructured":"Wei C, Yang C, Wang S, Shi D, Zhang C, Lin X, Liu Q, Dou R, Xiong B. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 2019;18:64.","journal-title":"Mol Cancer"},{"key":"1967_CR23","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-20-4459","volume":"27","author":"M Taki","year":"2021","unstructured":"Taki M, Abiko K, Ukita M, Murakami R, Yamanoi K, Yamaguchi K, Hamanishi J, Baba T, Matsumura N, Mandai M. Tumor Immune Microenvironment during epithelial-mesenchymal transition. Clin Cancer Res. 2021;27:4669\u201379.","journal-title":"Clin Cancer Res"},{"key":"1967_CR24","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.biocel.2008.10.015","volume":"41","author":"G Ren","year":"2009","unstructured":"Ren G, Zhang G, Dong Z, Liu Z, Li L, Feng Y, Su D, Zhang Y, Huang B, Lu J. Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers. Int J Biochem Cell Biol. 2009;41:1094\u2013101.","journal-title":"Int J Biochem Cell Biol"},{"key":"1967_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.drup.2017.01.001","volume":"30","author":"S Wottrich","year":"2017","unstructured":"Wottrich S, Kaufhold S, Chrysos E, Zoras O, Baritaki S, Bonavida B. Inverse correlation between the metastasis suppressor RKIP and the metastasis inducer YY1: contrasting roles in the regulation of chemo\/immuno-resistance in cancer. Drug Resist Updat. 2017;30:28\u201338.","journal-title":"Drug Resist Updat"},{"key":"1967_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13046-015-0177-y","volume":"34","author":"G Zhao","year":"2015","unstructured":"Zhao G, Li Q, Wang A, Jiao J. YY1 regulates melanoma tumorigenesis through a miR-9 ~ RYBP axis. J Exp Clin Cancer Res. 2015;34:66.","journal-title":"J Exp Clin Cancer Res"},{"key":"1967_CR27","doi-asserted-by":"publisher","first-page":"12697","DOI":"10.18632\/oncotarget.3708","volume":"6","author":"F Morra","year":"2015","unstructured":"Morra F, Luise C, Merolla F, Poser I, Visconti R, Ilardi G, Paladino S, Inuzuka H, Guggino G, Monaco R, et al. FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC. Oncotarget. 2015;6:12697\u2013709.","journal-title":"Oncotarget"},{"key":"1967_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/mc.22905","volume":"58","author":"T Hu","year":"2019","unstructured":"Hu T, Zhang J, Sha B, Li M, Wang L, Zhang Y, Liu X, Dong Z, Liu Z, Li P, Chen P. Targeting the overexpressed USP7 inhibits esophageal squamous cell carcinoma cell growth by inducing NOXA-mediated apoptosis. Mol Carcinog. 2019;58:42\u201354.","journal-title":"Mol Carcinog"},{"key":"1967_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1573406413666171020115539","volume":"14","author":"J Zhou","year":"2018","unstructured":"Zhou J, Wang J, Chen C, Yuan H, Wen X, Sun H. USP7: Target Validation and Drug Discovery for Cancer Therapy. Med Chem. 2018;14:3\u201318.","journal-title":"Med Chem"},{"key":"1967_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12013-011-9185-5","volume":"60","author":"B Nicholson","year":"2011","unstructured":"Nicholson B, Suresh Kumar KG. The multifaceted roles of USP7: new therapeutic opportunities. Cell Biochem Biophys. 2011;60:61\u20138.","journal-title":"Cell Biochem Biophys"},{"key":"1967_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/cei.12953","volume":"189","author":"P Castro-Sanchez","year":"2017","unstructured":"Castro-Sanchez P, Ramirez-Munoz R, Lamana A, Ortiz A, Gonzalez-Alvaro I, Roda-Navarro P. mRNA profiling identifies low levels of phosphatases dual-specific phosphatase-7 (DUSP7) and cell division cycle-25B (CDC25B) in patients with early arthritis. Clin Exp Immunol. 2017;189:113\u20139.","journal-title":"Clin Exp Immunol"},{"key":"1967_CR32","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1159\/000484062","volume":"43","author":"M Wang","year":"2017","unstructured":"Wang M, Zhang Y, Wang T, Zhang J, Zhou Z, Sun Y, Wang S, Shi Y, Luan X, Zhang Y, et al. The USP7 inhibitor P5091 induces cell death in ovarian cancers with different P53 status. Cell Physiol Biochem. 2017;43:1755\u201366.","journal-title":"Cell Physiol Biochem"},{"key":"1967_CR33","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.molcel.2015.07.033","volume":"59","author":"YH Hao","year":"2015","unstructured":"Hao YH, Fountain MD Jr, Fon Tacer K, Xia F, Bi W, Kang SH, Patel A, Rosenfeld JA, Le Caignec C, Isidor B, et al. USP7 Acts as a Molecular Rheostat to promote WASH-Dependent endosomal protein recycling and is mutated in a human neurodevelopmental disorder. Mol Cell. 2015;59:956\u201369.","journal-title":"Mol Cell"},{"key":"1967_CR34","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/onc.2015.149","volume":"35","author":"A Zlatanou","year":"2016","unstructured":"Zlatanou A, Sabbioneda S, Miller ES, Greenwalt A, Aggathanggelou A, Maurice MM, Lehmann AR, Stankovic T, Reverdy C, Colland F, et al. USP7 is essential for maintaining Rad18 stability and DNA damage tolerance. Oncogene. 2016;35:965\u201376.","journal-title":"Oncogene"},{"key":"1967_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","volume":"52","author":"JS O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ. Resistance to PD1\/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71\u201381.","journal-title":"Cancer Treat Rev"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01967-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-023-01967-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01967-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T05:10:15Z","timestamp":1688533815000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-023-01967-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1967"],"URL":"https:\/\/doi.org\/10.1186\/s12951-023-01967-3","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,5]]},"assertion":[{"value":"12 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments were conducted in accordance with the National Institutes of Health Animal Use Guidelines. The experiments were conducted in accordance with the guidelines of the Animal Ethics Committee of Tianjin International Joint Academy of Biomedicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}